Video Buzz v1

Related Bisphosphonate News

Bone Mineral Density Monitoring May Not Be Needed Up to 3 Years After ... - Medscape News

July 2, 2009 ? Monitoring bone mineral density (BMD) in postmenopausal women in the first 3 years after starting treatment with a potent bisphosphonate is not needed and may even be misleading, according to the results of a study reported in the ...

Potential Mislead And Uselessness In Monitoring Bone Density In Older ... - Medical News Today

A study published on bmj.com reports that monitoring bone mineral density in postmenopausal women taking osteoporosis drugs, such as bisphosphonates, is pointless and could be misleading. A major public health problem, osteoporosis particularly ...

EU Sanctions Novartis Drug for Steroid-Induced Osteoporosis - Genetic Engineering News

Novartis? bisphosphonate infusion, Aclasta®, received approval in the EU for the treatment of men and postmenopausal women with osteoporosis caused by long-term glucocorticoid therapy. The drug is already marketed in the U.S. for this indication ...

Once-yearly Aclasta® approved in EU to treat osteoporosis caused by ... - WebWire

* Steroids, widely used to treat inflammatory conditions, can cause bone loss and increase risk of fractures in up to 50% of patients on long-term therapy[1] * European approval based on data showing Aclasta better at increasing bone mass than oral ...

Aclasta(R) (zoledronic Acid 5mg) Approved In EU To Treat Steroid ... - Medical News Today

Aclasta® (zoledronic acid 5 mg)[1] has been approved in the European Union to treat men and post-menopausal women with osteoporosis caused by the long-term use of glucocorticoids, commonly known as steroids.1 The new indication for the treatment of ...

Bisphosphonate Podcasts

Do you prefer to listen to your bisphosphonate gossip? Check out Podzy Podcast Directory > Bisphosphonate.

Bisphosphonate Products

Looking for bisphosphonate related products, then look no further. Try our new Bisphosphonate Shop.